 | • レポートコード：MRC-IM30189 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥369,852 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥665,852 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の調査レポートによると、世界の多形性膠芽腫治療薬市場規模は2021年に18億ドルに達しました。今後、2027年には29億ドルになり、2022年から2022年の間に年平均7.9％成長すると予測しています。本調査レポートでは、多形性膠芽腫治療薬の世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、薬物種類別（テモゾロミド、ベバシズマブ、カルムスチン、放射線増感剤、その他）分析、投与経路別（経口、非経口）分析、分子種類別（低分子、生物製剤）分析、流通チャネル別（病院、薬局、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals, etc.などが含まれています。 ・序論 ・調査範囲・手法 ・エグゼクティブサマリー ・イントロダクション ・世界の多形性膠芽腫治療薬市場規模：薬物種類別 - テモゾロミドの市場規模 - ベバシズマブの市場規模 - カルムスチンの市場規模 - 放射線増感剤の市場規模 - その他薬物の市場規模 ・世界の多形性膠芽腫治療薬市場規模：投与経路別 - 経口型多形性膠芽腫治療薬の市場規模 - 非経口型多形性膠芽腫治療薬の市場規模 ・世界の多形性膠芽腫治療薬市場規模：分子種類別 - 低分子治療薬の市場規模 - 生物製剤の市場規模 ・世界の多形性膠芽腫治療薬市場規模：流通チャネル別 - 病院チャネルの市場規模 - 薬局チャネルの市場規模 - その他チャネルの市場規模 ・世界の多形性膠芽腫治療薬市場規模：地域別 - 北米の多形性膠芽腫治療薬市場規模 - アジアの多形性膠芽腫治療薬市場規模 - 欧州の多形性膠芽腫治療薬市場規模 - 中南米の多形性膠芽腫治療薬市場規模 - 中東・アフリカの多形性膠芽腫治療薬市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global glioblastoma multiforme treatment market size reached US$ 1.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2027, exhibiting a growth rate (CAGR) of 7.9% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on drug type, route of administration, type of molecule and distribution channel.
Breakup by Drug Type:
Temozolomide
Bevacizumab
Carmustine
Radiosensitizers
Others
Breakup by Route of Administration:
Oral
Parenteral
Breakup by Type of Molecule:
Small Molecule
Biologics
Breakup by Distribution Channel:
Hospitals
Pharmacies
Others
Breakup by Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals, etc.
IMARC Group’s latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.
Key Questions Answered in This Report:
How has the global glioblastoma multiforme treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global glioblastoma multiforme treatment industry?
What are the key regional markets in the global glioblastoma multiforme treatment industry?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the type of molecule?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global glioblastoma multiforme treatment industry?
What are the key driving factors and challenges in the global glioblastoma multiforme treatment industry?
What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
What is the degree of competition in the global glioblastoma multiforme treatment industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Glioblastoma Multiforme Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Type
5.5 Market Breakup by Route of Administration
5.6 Market Breakup by Type of Molecule
5.7 Market Breakup by Distribution Channel
5.8 Market Breakup by Region
5.9 Market Forecast
6 Market Breakup by Drug Type
6.1 Temozolomide
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Bevacizumab
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Carmustine
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Radiosensitizers
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Parenteral
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Type of Molecule
8.1 Small Molecule
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Biologics
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Europe
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Asia Pacific
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Middle East and Africa
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Latin America
10.5.1 Market Trends
10.5.2 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Sun Pharmaceutical Industries
15.3.2 Celldex Therapeutics
15.3.3 Pfizer
15.3.4 F. Hoffmann La Roche
15.3.5 Bristol-Myers Squibb
15.3.6 Teva Pharmaceuticals
15.3.7 Exelixis
15.3.8 Angiochem
15.3.9 Arbor Pharmaceuticals
Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion US$), 2016 - 2021
Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2021
Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2021
Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2021
Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2021
Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter’s Five Forces Analysis
Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million US$), 2016 & 2021
Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million US$), 2022-2027
Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million US$), 2016 & 2021
Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million US$), 2022-2027
Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million US$), 2016 & 2021
Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million US$), 2022-2027
Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2022-2027